

Press release

OTOFARMA: 2026 CORPORATE EVENTS CALENDAR

Naples, 28 January 2026 – Otofarma – a leading group in the production of hearing aids distributed mainly through the pharmaceutical channel, with over 30 years of experience in the hearing care sector – announces that its Board of Directors met today to approve, pursuant to Article 17 of the Euronext Growth Milan Issuers' Regulations, the calendar of corporate events for the year 2026, as shown below:

DATA	EVENTO
30 March 2026	Board of Directors meeting to approve the draft Financial Statements and Consolidated Financial Statements as at 31 December 2025
30 Aprile 2026 (first call) - 19 May 2026 (second call)	Ordinary Shareholders' Meeting to approve the Financial Statements and review the Consolidated Financial Statements as at 31 December 2025
29 September 2026	Board of Directors' meeting to approve the consolidated half-yearly financial report as at 30 June 2026, voluntarily submitted to limited audit

Otofarma will promptly notify the market of any changes to the above dates.

The calendar of corporate events will be available on the Company's website www.otofarmaspa.it in the 'Investor Relations/Financial Calendar' section.

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the green shoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A.- Investor relations



Anna Incarnato Bartolomucci
E-mail: investor.relations@otofarma.it
mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com
mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146